83 related articles for article (PubMed ID: 24388532)
1. Severe thrombocytopenia induced by second exposure to trastuzumab can be alleviated by prolonging the interval between treatments.
Zeng RC; Dai XX; Xie FY; Chen ED; Qu JM; Hu XQ
Clin Breast Cancer; 2014 Apr; 14(2):e69-72. PubMed ID: 24388532
[No Abstract] [Full Text] [Related]
2. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia.
Choi JH; Han HS; Lee HC; Lee OJ; Kim JT; Lim SN; Lee KH; Kim ST
Onkologie; 2011; 34(11):621-4. PubMed ID: 22104159
[TBL] [Abstract][Full Text] [Related]
3. Severe thrombocytopenia related to long-term trastuzumab exposure.
Aguirre E; Taberner T; Luaña A; Morales S; Llombart A
Tumori; 2013; 99(1):e1-2. PubMed ID: 23549016
[TBL] [Abstract][Full Text] [Related]
4. Successful use of trastuzumab following cardiac resynchronisation therapy.
Claridge S; Chakrabarti A; Greaves K; Boos CJ
Int J Cardiol; 2013 Jun; 166(2):e33-4. PubMed ID: 23427862
[No Abstract] [Full Text] [Related]
5. Trastuzumab-related thrombocytopenia: always a self-limiting complication?
Drudi F; Gianni L; Fantini M; Ravaioli A
Ann Oncol; 2010 Mar; 21(3):668-669. PubMed ID: 20032121
[No Abstract] [Full Text] [Related]
6. Severe thrombocytopenia induced by a single infusion of trastuzumab.
Parikh O; Neave F; Palmieri C
Clin Breast Cancer; 2008 Jun; 8(3):285-6. PubMed ID: 18650161
[TBL] [Abstract][Full Text] [Related]
7. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
[TBL] [Abstract][Full Text] [Related]
8. Tako-Tsubo syndrome after trastuzumab - an unusual complication of chemotherapy for breast cancer.
Khanji M; Nolan S; Gwynne S; Pudney D; Ionescu A
Clin Oncol (R Coll Radiol); 2013 May; 25(5):329. PubMed ID: 23434354
[No Abstract] [Full Text] [Related]
9. Drug-induced immune thrombocytopenia.
Cathomas R; Goldhirsch A; von Moos R
N Engl J Med; 2007 Nov; 357(18):1870-1; author reply 1871. PubMed ID: 17985437
[No Abstract] [Full Text] [Related]
10. Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision.
Wong HH; Collins J; McAdam K; Wilson C
Oncology; 2014; 86(1):22-3. PubMed ID: 24335099
[No Abstract] [Full Text] [Related]
11. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
12. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
13. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
14. Gradual thrombocytopenia induced by long-term trastuzumab exposure.
Miarons M; Velasco M; Campins L; Fernández S; Gurrera T; Lopez-Viaplana L
J Clin Pharm Ther; 2016 Oct; 41(5):563-5. PubMed ID: 27425556
[TBL] [Abstract][Full Text] [Related]
15. [Long-term survival of a patient with giant liver metastatic breast cancer treated with trastuzumab].
Okada N; Narita Y; Nanno Y; Shimaguchi M; Imamura K; Inoue R; Nakamura T; Takada M; Kato H; Suzuki O; Ambo Y; Nakamura F; Kishida A; Kashimura N; Matsunami O
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1399-402. PubMed ID: 22996777
[TBL] [Abstract][Full Text] [Related]
16. [An unexpected and severe infusion reaction induced by trastuzumab].
Sacramento Díaz-Carrasco M; Ramírez C; Montenegro S; Alonso-Romero JL
Farm Hosp; 2014 May; 38(3):254-5. PubMed ID: 24951913
[TBL] [Abstract][Full Text] [Related]
17. [Heart failure in women treated with adjuvant trastuzumab for breast cancer].
Tarantini L; Feola M; Albini A; Gori S; Foglietta J; Cicoira MA; Pulignano G
G Ital Cardiol (Rome); 2012 May; 13(5 Suppl 1):54S-62S. PubMed ID: 23678535
[TBL] [Abstract][Full Text] [Related]
18. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
20. [Successful ventilator weaning by trastuzumab in a HER2-positive breast cancer patient with multiple lung metastases].
Matsuda T; Fujita H; Kunimoto Y; Hosono M; Kimura T; Hayashi T; Maeda T; Yamakawa J; Maeda N; Mizumoto T; Maruyama S; Uenaka Y; Ogino K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):773-6. PubMed ID: 23863656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
